Details for New Drug Application (NDA): 207975
✉ Email this page to a colleague
NDA 207975 describes VANTRELA ER, which is a drug marketed by Teva Branded Pharm and is included in one NDA. There are three patents protecting this drug. Additional details are available on the VANTRELA ER profile page.
The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the hydrocodone bitartrate profile page.
The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the hydrocodone bitartrate profile page.
Summary for 207975
| Tradename: | VANTRELA ER |
| Applicant: | Teva Branded Pharm |
| Ingredient: | hydrocodone bitartrate |
| Patents: | 3 |
Medical Subject Heading (MeSH) Categories for 207975
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 15MG | ||||
| Approval Date: | Jan 17, 2017 | TE: | RLD: | Yes | |||||
| Patent: | 8,445,018 | Patent Expiration: | Jul 31, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | 9,216,176 | Patent Expiration: | Sep 13, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | 9,572,803 | Patent Expiration: | Sep 13, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
